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Abstract 
Background: Toxoplasmosis was recently included as a neglected disease by the Center for Disease Control. Ocular 
toxoplasmosis is one clinical presentation of congenital or acquired infection. The laboratory diagnosis is being used 
worldwide to support the clinical diagnosis and imaging. The aim of this study was to evaluate the use of serology 
and molecular methods to monitor acute OT in immunocompetent patients during treatment.
Methods: Five immunocompetent patients were clinically diagnosed with acute OT. The clinical evaluation was 
performed by ophthalmologic examination using the Early Treatment Diabetic Retinopathy Study, best‑corrected 
visual acuity, slit lamp biomicroscopy, fundoscopic examination with indirect binocular ophthalmoscopy color fundus 
photography, fluorescein angiography and spectral optical coherence tomography (OCT). Serology were performed 
by ELISA (IgA, IgM, IgG) and confirmed by ELFA (IgG, IgM). Molecular diagnoses were performed in peripheral blood 
by cPCR using the Toxoplasma gondii B1 gene as the marker. Follow‑up exams were performed on day +15 and day 
+45.
Results: Only five non‑immunocompromised male patients completed the follow up and their data were used for 
analysis. The mean age was 41.2 ± 11.3 years (median: 35; range 31–54 years). All of them were positive for IgG anti‑
bodies but with different profiles for IgM and IgA, as well as PCR. For all patients the OCT exam showed active lesions 
with the inner retinal layers being abnormally hyper‑reflective with full‑thickness disorganization of the retinal reflec‑
tive layers, which assumed a blurred reflective appearance and the retina was thickened.
Conclusions: The presence of IgA and IgM confirmed the acute infection and thus was in agreement with the clini‑
cal evaluation. Our results show the adopted treatment modified the serological profile of IgM antibodies and the PCR 
results, but not the IgG and IgA antibodies and that imaging is a good tool to follow‑up patients.
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Background
Toxoplasmic retinochoroiditis is a major cause of pos-
terior uveitis [1–3], it was considered the disease of the 
year in 2011 [4] and included in the list of neglected dis-
eases by the Centers for Disease Control (CDC) of the 
United States [5].
Toxoplasma gondii infection, the cause of this disease, 
may also occur during pregnancy during childhood or 
in adulthood. The clinical symptoms may appear soon 
after infection or delay with varying degrees of ocular 
involvement [6, 7]. T. gondii form latent cysts directly on 
the retina, which may be reactivated several years after 
the primary infection giving rise to retinochoroiditis. 
Although many episodes of retinochoroiditis are asymp-
tomatic, some result in loss of vision, pain, photophobia, 
either in isolation or together [8].
For a long time, toxoplasmic retinochoroiditis has been 
considered the most common eye lesion caused by T. 
gondii infection [9, 10]. Its prevalence appears to be quite 
variable in different countries, but estimates suggest 
that from 0.3 to 1 % of Europeans and North Americans 
develop this disease within 1–2 years of contracting the 
infection [9, 11, 12]. It is believed that the risk of develop-
ing this disease ranges from 18 in 100,000 individuals in 
the UK to as many as 382 in 100,000 individuals in West 
Africa [8, 13]. Furthermore, the risk of developing retino-
choroiditis among individuals who contracted congenital 
infection is as high as 20 % before the age of 6 years and 
that new eye lesions may first appear in adolescence [3, 
12, 14–16].
Studies in Brazil have shown that the prevalence of 
toxoplasma retinochoroiditis is variable but very high 
in adolescents and adults in some regions of the coun-
try; the disease ranges from 2 % in the southeast to 25 % 
in the southern region [10, 17–20]. A study in the State 
of Rio Grande do Sul revealed a prevalence of ocular 
toxoplasmosis of 21.3  % in over 13-year-old individu-
als and concluded that the disease is a consequence of 
postnatal infection [10]. In the State of Pernambuco, 
it was observed that 56.2 % of cases of posterior uveitis 
were due to T. gondii infection [21] and in the State of 
Rio Grande do Norte, 56.9 % of the patients analyzed in 
one investigation had bilateral lesions [22]. These studies 
make it clear that toxoplasmic retinochoroiditis is com-
mon in Brazil and thus an analysis of host risk associated 
with factors of this disease is justified. Furthermore, our 
recent study showed that the prevalence of toxoplasma 
retinochoroiditis is approximately 27  % among patients 
with eye diseases [23].
The growing interest in the investigation of toxo-
plasmosis has helped to develop strategies for early 
laboratory diagnosis and clinical intervention [24–
30]. Moreover, it has been found that imaging tests 
such as fundus photography, fluorescein angiography 
and optical coherence tomography (OCT) help in the 
assessment, registration and documentation of eye 
disease, thereby showing whether it is in the acute 
phase or quiescent, and can also be used to moni-
tor eye involvement in respect to T. gondii infection 
[3, 31–39]. OCT is a noninvasive test that provides 
data to evaluate morphological changes that occur in 
the retina, vitreous, and choroid during ocular toxo-
plasmosis and other ocular diseases. The objective of 
this study was to monitor the evolution of active ocu-
lar disease or acute relapse of ocular toxoplasmosis 
using serology and molecular tests and evaluate their 
applicability.
Methods
Ethical aspects of the study
This study was approved by the Ethics Committee of the 
Medicine School in São José do Rio Preto—FAMERP and 
the selected patients signed informed consent forms after 
being informed about the nature of the study including 
the objectives and laboratory procedures that would be 
performed.
Patients
In the period between August 2013 and July 2014, 
patients with clinical suspicion of active lesions or acute 
relapse of T. gondii infection were evaluated. Of a total 
of 31 patients enrolled and treated, five were selected 
because they adhered to the treatment regimen and were 
followed up for a period of 45 days (day 0; day +15;day 
+45). The and the start of the treatment were performed 
at day 0. New blood samples were collected for analysis at 
day +15 and day +45.
The five patients received clinical care and were sub-
mitted to all the proposed tests (serological diagnosis 
of toxoplasmosis, cPCR to detect T. gondii in peripheral 
blood; OCT and fundus photography) at each return 
consultation.
The inclusion criteria were patients with seroposi-
tive samples for toxoplasmosis, scarring of the retina 
characteristic of toxoplasmosis, and active retinocho-
roiditis lesion (satellite). Under 18-year-old patients were 
excluded as were immunosuppressed patients, patients 
receiving immunosuppression drugs and those with 
retinochoroiditis with clinical characteristics of other 
causes.
Blood sampling
Blood samples were collected in tubes with and without 
EDTA in all consultations. An investigation of T. gondii 
infection (IgM, IgG and IgA) was made and DNA was 
extracted from leukocytes.
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Eye exams
Clinical examination
All patients underwent detailed eye examinations includ-
ing visual acuity [the logMAR Early Treatment Diabetic 
Retinopathy Study (ETDRS) chart] with best correction 
according to standardization recommended by ETDRS 
[40], measurement of intraocular pressure by Goldmann 
applanation tonometry, biomicroscopy using a slit lamp, 
and stereoscopic biomicroscopy performed using a 78 
diopters lens (Volk) and classified according to the crite-
ria determined by the ETDRS.
The OCT was performed using the RTVue-100 scan-
ner with an axial image resolution and speed of five axial 
velocity of 26,000 frames per second using a program 
to measure the retinal thickness with the cursor placed 
according to the fixation of the patient or manually in the 
center of the fovea, when the foveal depression was vis-
ible. The analysis strategy utilized the macular thickness 
map measured in the central region of the retina.
The evaluation was performed using radial cuts (hori-
zontal and vertical of the line and cross line program) 
within the fundus area encompassing the toxoplasmosis 
ocular lesion. Whenever possible, three-dimensional OCT 
was conducted covering the entire retinochoroiditis lesion. 
In addition, standardized image acquisition programs such 
as MM5 (5 × 5 mm2 horizontal grid 11 by 11 vertical lines 
with 668 A-scans each and a 3 × 3 mm2 grid of six internal 
vertical and horizontal lines with 400 A-scans each), MM6 
(12 radial lines with 1024 A-scans each within 6  mm in 
diameter) and macula 3D (128 scan lines with 512 A-scans 
each within 6  ×  6  mm2) protocols were used, with all 
checks with signal strength of at least 40 (range 40.4–79.4).
Colored fundus photographs and fluorescent photo-
graphs were taken using a digital retinal camera (TRC-
50DX, Topcon Medical Systems) in order to document 
the macula region and optic nerve. Areas of progressive 
hyperfluorescence (leakage), impregnation of contrast 
(staining) and transmitted hyperfluorescence (window 
effect) were observed by fluorescein angiography. The 
progressive hyperfluorescence with delayed leakage of 
contrast was considered a sign of lesion activity.
Therapy regimen
After evaluating the patient at baseline and collecting 
blood samples, ocular toxoplasmosis was treated using 
the following protocol: sulfadiazine 1  g four times per 
day, pyrimethamine 50 mg daily, folinic acid 7.5 mg daily 
and prednisone 0.5 mg/kg/day for 4 weeks.
Detection of IgM, IgG and IgA anti‑T. gondii 
antibodies
IgM, IgG and IgA anti-T. gondii antibodies were inves-
tigated using the ELISA test with the ETI—TOXOK-M 
(IgM), ETI—TOXOK-G (IgG) and ETI—TOXOK-A 
(IgA) commercial kits (DiaSorin, Italy); the results were 
confirmed by enzyme-linked fluorescence immunoassay 
(ELFA) Vidas Toxo IgG and Vidas Toxo IgM (bioMérieux, 
France) according to manufacturer’s directions.
Molecular diagnosis of T. gondii infection
Extraction of genomic DNA
Genomic DNA was extracted from 5  mL of peripheral 
blood samples collected in EDTA as previously described 
[41] using the commercial QIAamp® DNA Blood Mini 
Kit (QIAGEN, The Netherlands) .
Molecular analysis to identify T. gondii
cPCR
Toxoplasma gondii was identified in blood samples using 
a previously described technique [41] that amplifies a 
final volume of 25 uL per reaction tube using the reagent 
GoTaq Hot Start Green Master Mix (Promega, USA). 
Each reaction tube (mix) contained 25  pmol of each 
primer, 1  U of Taq DNA polymerase, 10  mM Tris–HCl 
at pH 8.5, 50 mM KCl, 1.5 mM MgCl2, and 200 mM of 
each dNTP. Two negative controls (ultrapure water and 
genomic DNA negative for T. gondii) and a positive con-
trol (DNA extracted from the RH strain of T. gondii) were 
included in each amplification reaction.
The B22 and B23 primers, which amplify a 115-base 
pair (bp) fragment of the repeat region of the B1 gene, 
were utilized [42]. The HGH primers that amplify a 400-
bp fragment of the human growth hormone gene were 
used as a control of amplification and detection of PCR 
inhibitors. The amplicons were analyzed by electrophore-
sis in 2 % agarose gel, stained with ethidium bromide and 
viewed under ultraviolet light.
Data analysis
Data were analyzed descriptively to determine the impor-
tance of OCT to monitor the progression of active ocular 
disease or acute relapse due to infection by T. gondii.
Results
From the 31 patients enrolled in this study, only five com-
pleted the proposed follow up; all of them were male. The 
mean age was 41.2 ±  11.3  years (range 31–54; median: 
35). At the time of inclusion, all of them had positive 
serology for toxoplasmosis IgG antibodies.
Table 1 presents the data from serological tests for IgM, 
IgA and IgG anti-T. gondii antibodies of the five patients 
enrolled in this study and Table 2 shows the cPCR results. 
Figure  1 illustrates the results of color retinography 
imaging (a) fluorescein angiography (b) and OCT (c).
Table  3 shows the pattern of eye involvement of the 
patients with suspicion of acute ocular toxoplasmosis by 
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color retinography imaging, fluorescein angiography, and 
OCT.
Additional informations are described in Additional 
file 1.
Discussion
The aim of this study was to evaluate the use of serologi-
cal, molecular and imaging methods to monitor the sta-
tus and symptoms of patients clinically diagnosed with 
acute ocular toxoplasmosis. The B1 gene of T. gondii was 
used as target for molecular analysis since it has been 
described as more appropriated to characterize clini-
cal samples in Brazil in contrast with observations from 
other countries [24, 28, 30, 43–51].
The mean age of the five patients enrolled in this study 
was about 45-years- old, supporting reports that ocu-
lar toxoplasmosis affects young individuals [3, 52, 53]. 
It is possible that the disease is a result of congenitally 
acquired infection as the results do not allow us to verify 
the manner in which the toxoplasmosis was acquired.
The ELISA assay showed that one of the patients (case-
01) had acute infection due to the presence of IgM and 
IgA antibodies at the time of enrollment. This condition 
remained throughout the follow up which suggests that 
serological evidence of acute infection may continue even 
after treatment. This observation is in agreement with lit-
erature reports indicating that IgM antibodies persist in 
patients under treatment for ocular toxoplasmosis. It is 
also possible that this patient is a special case of individu-
als who have persistent IgM antibodies (IgM residual); 
this situation creates additional difficulties in laboratory 
diagnosis and in the continuation of treatment for long 
periods of time as it may lead to the impression that an 
infection is acute or a reactivation of infection [54–60].
By ELISA, one patient (case-02) was positive for IgM 
antibodies on day 0 but did not have evidence of IgA anti-
bodies in subsequent analyzes. Given that he was positive 
for IgG antibodies at enrollment in the study, it appears 
that he seroconverted to a chronic infection. However, 
these data are not enough to predict the time that the 
infection occurred. This condition seems to be common 
in patients infected with T. gondii irrespective of clinical 
evidence of ocular disease [25, 54, 56, 61, 62]. The other 
patients were not positive for IgM and IgA antibodies at 
inclusion in the study but the identification of IgG anti-
bodies was used to infer a chronic infection.
Except for one patient (case-01), all responded ade-
quately to the treatment regimen and the imaging tests 
showed a reduction of ocular inflammation during the 
follow-up period. This patient shows a different profile 
since he presented serological evidence of acute infection 
but the cPCR was negative during the follow up. Maybe 
this is a case of atypical strain infection not detected by 
B1 gene as previously described and the cPCR should be 
done using other set of primer as being reported in other 
regions of the world [3, 26, 44, 47, 63–67], but not in 
South American studies [30, 45, 48–50, 68–72].
There were no variations in the serological profile of 
three patients (case-03–05) but the cPCR results were 
positive at day 0 (cases 04 and 05), day 15 (case-03) and 
day 45 (case-05). These conditions of infection revealed 
by cPCR  in the peripheral blood may be the result of 
two possible situations: the presence of residual DNA 
or a false-positive result [25, 43, 48, 56]. These data are 
in agreement with that reported by Novais et  al. 2014 
[49] which found positive PCR in Brazilian patients 
Table 1 Results of serologic testing by ELISA for IgM, IgA and IgG antibodies of the five patients who completed the fol‑
low‑up (day 0, day +15, day +45)
P positive, N negative
Patient IgM IgA IgG
D0 D + 15 D + 45 D0 D + 15 D + 45 D0 D + 15 D + 45
Case‑01 P P P P P P P P P
Case‑02 P N N N N N P P P
Case‑03 N N N N N N P P P
Case‑04 N N N N N N P P P
Case‑05 N N N N N N P P P
Table 2 Results of  molecular tests (cPCR) of  the five 
patients who completed the follow‑up (day 0, day +15, 
day +45)
Patient D0 D + 15 D + 45
Case‑01 Negative Negative Negative
Case‑02 Negative Negative Positive
Case‑03 Negative Positive Negative
Case‑04 Positive Negative Negative
Case‑05 Positive Negative Positive
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presenting inactive toxoplasmic retinochoroidits lesions 
and with our previous report [41]. Additionally our study 
observed that one patient (case-05) had clinical evidence 
of reactivation of ocular disease based on the PCR 
results.
Fluorescein angiography showed progressive hyper-
fluorescence with delayed leakage of contrast and OCT 
showed that the locations of the lesions of all patients had 
abnormal inner layers of the retina with hyper-reflective 
thickened and blurred areas. The level of resolution of 
this imaging method is well suited to show the character-
ization of ocular lesions, including those resulting from 
T. gondii infection [36, 39, 73].
The presence of specific antibodies against T. gondii 
(IgM and IgA) identifies acute infection and confirms the 
clinical evaluation. Furthermore, our data suggest that 
the treatment used in this study may modify the sero-
logical profile of IgM antibodies and the result of cPCR, 
Fig. 1 Photodocumentation of pretreatment phase of one patient (case 1). a Fundus photography showing a satellite lesion (yellow square) of activ‑
ity suggestive of retinochoroiditis toxoplasmosis in the macula region and a healed retinochoroiditis lesion (blue circle); b fluorescein angiography 
showing a satellite lesion suggestive of activity of toxoplasmosis (yellow rectangle) in the macula region and a healed retinochoroiditis lesion (blue 
circle); c increases in the thickness of the inner retinal layers in perimacular regions (arrows) seen by optical coherence tomography
Table 3 Eye involvement of  the five patients with  suspi‑
cion of acute ocular toxoplasmosis
Patient Acute ocular involvement Previous scarring
Right eye Left eye Right eye Left eye
Case‑01 No Yes No Yes
Case‑02 Yes No No No
Case‑03 NoF Yes No Yes
Case‑04 Yes No Yes No
Case‑05 No Yes No Yes
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but not the serological profile of IgG and IgA antibod-
ies. Exceptions to this observation can be seem among 
patients with tendency to remain with residual IgM spe-
cific antibodies [25, 49, 56, 58, 59, 74, 75].
The present investigation was limited by the small num-
ber of patients evaluated and included. Would be desirable 
studies with a large amount of patients around the world 
and in Brazil which could confirm the results reported here.
Conclusion
In conclusion, blood tests are useful to monitor ocular 
toxoplasmosis and to determine whether the infection is 
acute or chronic. Molecular analysis by PCR helps to iden-
tify possible parasitemia and monitor the effectiveness of 
treatment as therapy together with the immune response 
should eliminate parasites circulating in the peripheral 
blood. Finally, this study shows that imaging tests are 
excellent noninvasive tools of photo documentation and 
to monitor inflammation and subsequent scarring of areas 
damaged by the parasite during ocular toxoplasmosis.
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